Nicaise Ndembi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6940266/publications.pdf

Version: 2024-02-01

201575 161767 3,462 111 27 54 citations h-index g-index papers 123 123 123 4345 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Disengagement from HIV care and failure of second-line therapy in Nigeria. Journal of Acquired Immune Deficiency Syndromes (1999), 2022, Publish Ahead of Print, .	0.9	1
2	Final HIV status outcome for HIV-exposed infants at 18 months of age in nine states and the Federal Capital Territory, Nigeria. PLoS ONE, 2022, 17, e0263921.	1.1	1
3	Dynamics of the infant gut microbiota in the first 18 months of life: the impact of maternal HIV infection and breastfeeding. Microbiome, 2022, 10, 61.	4.9	11
4	Field evaluation of HIV-1 viral load monitoring in adults and children receiving antiretroviral treatment in Nigeria by dried blood spot testing with RealTime HIV-1 on m2000. Journal of Clinical Virology, 2021, 135, 104694.	1.6	6
5	Time to Scale-up Research Collaborations to Address the Global Impact of COVID-19 – A Commentary. Health Behavior and Policy Review, 2021, 8, 277-280.	0.3	18
6	Hepatitis B virus infection among men who have sex with men and transgender women living with or at risk for HIV: a cross sectional study in Abuja and Lagos, Nigeria. BMC Infectious Diseases, 2021, 21, 654.	1.3	11
7	Deep sequencing of HIV-1 reveals extensive subtype variation and drug resistance after failure of first-line antiretroviral regimens in Nigeria. Journal of Antimicrobial Chemotherapy, 2021, , .	1.3	8
8	Evaluating the Jaccard Similarity Index as a Persistence Measure of Multiple Anal Human Papillomavirus among Nigerian Men Who Have Sex with Men. Sexually Transmitted Diseases, 2021, Publish Ahead of Print, .	0.8	0
9	Seroreactivity against Marburg or related filoviruses in West and Central Africa. Emerging Microbes and Infections, 2020, 9, 124-128.	3.0	8
10	Genetic clustering analysis for HIV infection among MSM in Nigeria: implications for intervention. Aids, 2020, 34, 227-236.	1.0	5
11	Elevated Plasma Levels of sCD14 and MCP-1 Are Associated With HIV Associated Neurocognitive Disorders Among Antiretroviral-Naive Individuals in Nigeria. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 84, 196-202.	0.9	12
12	Association of age with healthcare needs and engagement among Nigerian men who have sex with men and transgender women: crossâ€sectional and longitudinal analyses from an observational cohort. Journal of the International AIDS Society, 2020, 23, e25599.	1.2	21
13	Retention of a cohort of men who have sex with men and transgender women at risk for and living with HIV in Abuja and Lagos, Nigeria: a longitudinal analysis. Journal of the International AIDS Society, 2020, 23, e25592.	1.2	15
14	Cohort profile: the Nigerian HIV geriatric cohort study. BMC Public Health, 2020, 20, 1797.	1.2	3
15	Oral sex practices among men who have sex with men and transgender women at risk for and living with HIV in Nigeria. PLoS ONE, 2020, 15, e0238745.	1.1	6
16	High-Risk Human Papillomavirus Persistence and Anal Microbiota Among Nigerian Men Who Have Sex With Men Living With or At Risk for HIV. JCO Global Oncology, 2020, 6, 26-27.	0.8	2
17	Predictors of first-line antiretroviral therapy failure among adults and adolescents living with HIV/AIDS in a large prevention and treatment program in Nigeria. AIDS Research and Therapy, 2020, 17, 64.	0.7	5
18	Multiple HPV infections among men who have sex with men engaged in anal cancer screening in Abuja, Nigeria. Papillomavirus Research (Amsterdam, Netherlands), 2020, 10, 100200.	4. 5	12

#	Article	IF	Citations
19	Computational MHC-I epitope predictor identifies 95% of experimentally mapped HIV-1 clade A and D epitopes in a Ugandan cohort. BMC Infectious Diseases, 2020, 20, 172.	1.3	5
20	High prevalence of integrase mutation L74I in West African HIV-1 subtypes prior to integrase inhibitor treatment. Journal of Antimicrobial Chemotherapy, 2020, 75, 1575-1579.	1.3	12
21	Characterisation of HIV-1 Molecular Epidemiology in Nigeria: Origin, Diversity, Demography and Geographic Spread. Scientific Reports, 2020, 10, 3468.	1.6	14
22	Epidemiologic and viral predictors of antiretroviral drug resistance among persons living with HIV in a large treatment program in Nigeria. AIDS Research and Therapy, 2020, 17, 7.	0.7	9
23	Satisfaction with high-resolution anoscopy for anal cancer screening among men who have sex with men: a cross-sectional survey in Abuja, Nigeria. BMC Cancer, 2020, 20, 98.	1.1	3
24	Implementation of and Early Outcomes From Anal Cancer Screening at a Community-Engaged Health Care Facility Providing Care to Nigerian Men Who Have Sex With Men. Journal of Global Oncology, 2019, 5, 1-11.	0.5	9
25	Predictors of loss to follow-up in art experienced patients in Nigeria: a 13Âyear review (2004–2017). AIDS Research and Therapy, 2019, 16, 30.	0.7	21
26	Performance and trend for quality of service in a large HIV/AIDS treatment program in Nigeria. AIDS Research and Therapy, 2019, 16, 29.	0.7	5
27	Social barriers in accessing care by clients who returned to HIV care after transient loss to follow-up. AIDS Research and Therapy, 2019, 16, 17.	0.7	12
28	Correlates and determinants of Early Infant Diagnosis outcomes in North-Central Nigeria. AIDS Research and Therapy, 2019, 16, 27.	0.7	6
29	Serologic Prevalence of Ebola Virus in Equatorial Africa. Emerging Infectious Diseases, 2019, 25, 911-918.	2.0	18
30	Individual and Sexual Network Predictors of HIV Incidence Among Men Who Have Sex With Men in Nigeria. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 444-453.	0.9	42
31	New Subtype B Containing HIV-1 Circulating Recombinant of sub-Saharan Africa Origin in Nigerian Men Who Have Sex With Men. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, 578-584.	0.9	8
32	Distinct rates and patterns of spread of the major HIV-1 subtypes in Central and East Africa. PLoS Pathogens, 2019, 15, e1007976.	2.1	37
33	Anal Microbial Patterns and Oncogenic Human Papillomavirus in a Pilot Study of Nigerian Men Who Have Sex with Men at Risk for or Living with HIV. AIDS Research and Human Retroviruses, 2019, 35, 267-275.	0.5	7
34	Hepatitis C virus surveillance and identification of human pegivirus 2 in a large Cameroonian cohort. Journal of Viral Hepatitis, 2019, 26, 30-37.	1.0	14
35	Global and regional molecular epidemiology of HIV-1, 1990–2015: a systematic review, global survey, and trend analysis. Lancet Infectious Diseases, The, 2019, 19, 143-155.	4.6	255
36	Association between HIV-1 subtype and drug resistance in Nigerian infants. Journal of Antimicrobial Chemotherapy, 2019, 74, 172-176.	1.3	4

3

#	Article	IF	CITATIONS
37	Transmitted, Pre-treatment and Acquired Antiretroviral Drug Resistance among Men who have Sex with Men and Transgender Women Living with HIV in Nigeria. Antiviral Therapy, 2019, 24, 595-601.	0.6	5
38	Cognitive Function Among Antiretroviral Treatment–Naive Individuals Infected With Human Immunodeficiency Virus Type 1 Subtype G Versus CRF02_AG in Nigeria. Clinical Infectious Diseases, 2018, 66, 1448-1453.	2.9	3
39	ARCHITECT HIV Combo Ag/Ab and RealTime HIV-1 Assays Detect Diverse HIV Strains in Clinical Specimens. AIDS Research and Human Retroviruses, 2018, 34, 314-318.	0.5	8
40	Serum Albumin as a Prognostic Marker for Serious Non-AIDS Endpoints in the Strategic Timing of Antiretroviral Treatment (START) Study. Journal of Infectious Diseases, 2018, 217, 405-412.	1.9	17
41	High Prevalence of HIV Drug Resistance Among Newly Diagnosed Infants Aged <18 Months: Results From a Nationwide Surveillance in Nigeria. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, e1-e7.	0.9	18
42	Universal Target Capture of HIV Sequences From NGS Libraries. Frontiers in Microbiology, 2018, 9, 2150.	1.5	21
43	Plasma HIV RNA level is associated with neurocognitive function among HIV-1-infected patients in Nigeria. Journal of NeuroVirology, 2018, 24, 712-719.	1.0	11
44	Antiretroviral Drugs Alter the Content of Extracellular Vesicles from HIV-1-Infected Cells. Scientific Reports, 2018, 8, 7653.	1.6	58
45	Individual and Network Factors Associated With HIV Care Continuum Outcomes Among Nigerian MSM Accessing Health Care Services. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 79, e7-e16.	0.9	20
46	Prevalence of anti-hepatitis C antibodies and its co-infection with HIV in rural Cameroon. BMC Research Notes, 2018, 11, 459.	0.6	7
47	High prevalence of hepatitis delta virus in Cameroon. Scientific Reports, 2018, 8, 11617.	1.6	21
48	Sexual partner characteristics and incident rectalNeisseria gonorrhoeaeandChlamydia trachomatisinfections among gay men and other men who have sex with men (MSM): a prospective cohort in Abuja and Lagos, Nigeria. Sexually Transmitted Infections, 2017, 93, 348-355.	0.8	14
49	Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration. EBioMedicine, 2017, 18, 225-235.	2.7	28
50	Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study. Lancet Infectious Diseases, The, 2017, 17, 296-304.	4.6	58
51	Phylodynamic analysis to inform prevention efforts in mixed HIV epidemics. Virus Evolution, 2017, 3, vex014.	2.2	24
52	HIV-1 transmission networks in high risk fishing communities on the shores of Lake Victoria in Uganda: A phylogenetic and epidemiological approach. PLoS ONE, 2017, 12, e0185818.	1.1	23
53	High levels of preâ€treatment HIV drug resistance and treatment failure in Nigerian children. Journal of the International AIDS Society, 2016, 19, 21140.	1.2	32
54	Brief Report: Geographical Variation in Prevalence of Cryptococcal Antigenemia Among HIV-Infected, Treatment-Naive Patients in Nigeria: A Multicenter Cross-Sectional Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 73, 117-121.	0.9	20

#	Article	IF	Citations
55	Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. Lancet Infectious Diseases, The, 2016, 16, 565-575.	4.6	217
56	Macrophage Inflammatory Protein-1 Beta and Interferon Gamma Responses in Ugandans with HIV-1 Acute/Early Infections. AIDS Research and Human Retroviruses, 2016, 32, 237-246.	0.5	7
57	Active tracking of rejected dried blood samples in a large program in Nigeria. World Journal of Virology, 2016, 5, 73.	1.3	7
58	Doing No Harm? Adverse Events in a Nation-Wide Cohort of Patients with Multidrug-Resistant Tuberculosis in Nigeria. PLoS ONE, 2015, 10, e0120161.	1.1	28
59	Editorial (Thematic Issue: Adherence to Antiretroviral Therapy, Retention in Care and HIV Drug) Tj ETQq1 1 0.784	-314 rgBT	/Ogerlock 10
60	Correlates of Patient Retention in HIV Care and Treatment Programs in Nigeria. Current HIV Research, 2015, 13, 300-307.	0.2	18
61	Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis. PLoS Medicine, 2015, 12, e1001810.	3.9	188
62	Intrapatient Evolutionary Dynamics of Human Immunodeficiency Virus Type 1 in Individuals Undergoing Alternative Treatment Strategies with Reverse Transcriptase Inhibitors. AIDS Research and Human Retroviruses, 2015, 31, 749-756.	0.5	2
63	Frequencies of Gag-restricted T-cell escape "footprints―differ across HIV-1 clades A1 and D chronically infected Ugandans irrespective of host HLA B alleles. Vaccine, 2015, 33, 1664-1672.	1.7	9
64	HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing. PLoS ONE, 2015, 10, e0145772.	1.1	72
65	Improved Performance of COBAS AmpliPrep/COBAS TaqMan Version 2.0 Assay Over Amplicor Monitor Version 1.5 in the Quantification of HIV-1 RNA Viral Load in Abuja, Nigeria. Current HIV Research, 2015, 13, 262-267.	0.2	1
66	Adherence to Anti-Retroviral Therapy in North Central Nigeria. Current HIV Research, 2015, 13, 268-278.	0.2	8
67	Performance of Genotype MTBDRplus in the Detection of Resistance to Rifampicin and Isoniazid Among Clinical Mycobacteria Isolates in Ilorin, Nigeria. Current HIV Research, 2015, 13, 308-314.	0.2	2
68	Socio-Demographic and Adherence Factors Associated with Viral Load Suppression in HIV-Infected Adults Initiating Therapy in Northern Nigeria: A Randomized Controlled Trial of a Peer Support Intervention. Current HIV Research, 2015, 13, 279-285.	0.2	21
69	Update on HIV-1 acquired and transmitted drug resistance in Africa. AIDS Reviews, 2015, 17, 3-20.	0.5	41
70	Rates of HIV-1 superinfection and primary HIV-1 infection are similar in female sex workers in Uganda. Aids, 2014, 28, 2147-2152.	1.0	20
71	Long-Term Outcome of Second-Line Antiretroviral Therapy in Resource-Limited Settings. Journal of the International Association of Providers of AIDS Care, 2014, 13, 366-371.	0.6	5
72	Tenofovir-based regimens associated with less drug resistance in HIV-1-infected Nigerians failing first-line antiretroviral therapy. Aids, 2013, 27, 553-561.	1.0	21

#	Article	IF	CITATIONS
73	Short Communication: HIV Type 1 Transmitted Drug Resistance and Evidence of Transmission Clusters Among Recently Infected Antiretroviral-Naive Individuals from Ugandan Fishing Communities of Lake Victoria. AIDS Research and Human Retroviruses, 2013, 29, 788-795.	0.5	24
74	Effect of pregnancy on immunological and virological outcomes of women on ART: a prospective cohort study in rural Uganda, 2004–2009. Tropical Medicine and International Health, 2012, 17, 343-352.	1.0	12
75	Transmitted Antiretroviral Drug Resistance Among Drug-Naive Female Sex Workers With Recent Infection in Kampala, Uganda. Clinical Infectious Diseases, 2012, 54, S339-S342.	2.9	11
76	Mucosal Transmission of Human Immunodeficiency Virus. Current HIV Research, 2012, 10, 3-8.	0.2	46
77	HIV Type 1 Subtype Distribution, Multiple Infections, Sexual Networks, and Partnership Histories in Female Sex Workers in Kampala, Uganda. AIDS Research and Human Retroviruses, 2012, 28, 357-365.	0.5	27
78	Profile of T Cell Recognition of HIV Type 1 Consensus Group M Gag and Nef Peptides in a Clade A1- and D-Infected Ugandan Population. AIDS Research and Human Retroviruses, 2012, 28, 384-392.	0.5	11
79	Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet, The, 2012, 380, 1250-1258.	6.3	324
80	Short Communication: High Prevalence of Transmitted Antiretroviral Drug Resistance Among Newly HIV Type 1 Diagnosed Adults in Mombasa, Kenya. AIDS Research and Human Retroviruses, 2012, 28, 1033-1037.	0.5	34
81	Phylodynamics of the HIV-1 CRF02_AG clade in Cameroon. Infection, Genetics and Evolution, 2012, 12, 453-460.	1.0	52
82	Update on HIV-1 diversity in Africa: a decade in review. AIDS Reviews, 2012, 14, 83-100.	0.5	91
83	Can Oral Fluid Testing Be Used to Replace Blood-Based HIV Rapid Testing to Scale up Access to Diagnosis and Treatment in Cameroon?. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, e115-e117.	0.9	4
84	Transmitted antiretroviral drug resistance among newly HIV-1 diagnosed young individuals in Kampala. Aids, 2011, 25, 905-910.	1.0	56
85	Multiple HIV-1 infections with evidence of recombination in heterosexual partnerships in a low risk Rural Clinical Cohort in Uganda. Virology, 2011, 411, 113-131.	1.1	26
86	Confirmation of Putative HIV-1 Group P in Cameroon. Journal of Virology, 2011, 85, 1403-1407.	1.5	115
87	High Frequency of HIV-1 Dual Infections in Cameroon, West Central Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, e25-e27.	0.9	3
88	Lack of Minority K65R-Resistant Viral Populations Detected After Repeated Treatment Interruptions of Tenofovir/Zidovudine and Lamivudine in a Resource-Limited Setting. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 54, 215-216.	0.9	2
89	Viral Rebound and Emergence of Drug Resistance in the Absence of Viral Load Testing: A Randomized Comparison between Zidovudine‣amivudine plus Nevirapine and Zidovudine‣amivudine plus Abacavir. Journal of Infectious Diseases, 2010, 201, 106-113.	1.9	46
90	Near Full-Length Sequence of HIV Type 1 Subtype J Strain 04CMU11421 from Cameroon. AIDS Research and Human Retroviruses, 2010, 26, 693-697.	0.5	4

#	Article	IF	Citations
91	Evolution of Drug Resistance During 48 Weeks of Zidovudine/Lamivudine/Tenofovir in the Absence of Real-Time Viral Load Monitoring. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, 277-283.	0.9	20
92	Four New HIV-1 Group N Isolates from Cameroon: Prevalence Continues to Be Low. AIDS Research and Human Retroviruses, 2010, 26, 109-115.	0.5	47
93	HIV Type 1 Group M Subtype G in Cameroon: Five Genome Sequences. AIDS Research and Human Retroviruses, 2009, 25, 469-473.	0.5	10
94	Rapid detection of human immunodeficiency virus type 1 group M by a reverse transcription-loop-mediated isothermal amplification assay. Journal of Virological Methods, 2009, 157, 195-199.	1.0	25
95	Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial. Lancet, The, 2009, 374, 2080-2089.	6.3	217
96	Near Full-Length Genome Characterization of an HIV Type 1 CRF25_cpx Strain from Cameroon. AIDS Research and Human Retroviruses, 2008, 24, 1309-1314.	0.5	8
97	Molecular Characterization of Human Immunodeficiency Virus Type 1 (HIV-1) and HIV-2 in Yaoundelet Cameroon: Evidence of Major Drug Resistance Mutations in Newly Diagnosed Patients Infected with Subtypes Other than Subtype B. Journal of Clinical Microbiology, 2008, 46, 177-184.	1.8	50
98	HIV Type 2 Intergroup Recombinant Identified in Cameroon. AIDS Research and Human Retroviruses, 2008, 24, 86-91.	0.5	20
99	The Prevalence of Diverse HIV-1 Strains Was Stable in Cameroonian Blood Donors From 1996 to 2004. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 49, 432-439.	0.9	77
100	Near Full-Length Genome Characterization of Three Additional HIV Type 1 CRF13_cpx Strains from Cameroon. AIDS Research and Human Retroviruses, 2007, 23, 297-302.	0.5	15
101	Monitoring antiretroviral therapy in HIV/AIDS patients in resource-limited settings: CD4 counts or total lymphocyte counts?. International Journal of Infectious Diseases, 2007, 11, 157-160.	1.5	18
102	Exposure to SIVmnd-2 in Southern Cameroon: Public Health Implications. HIV and AIDS Review, 2007, 6, 16-19.	0.1	0
103	Identification of HIV Type 1 Group N Infections in a Husband and Wife in Cameroon: Viral Genome Sequences Provide Evidence for Horizontal Transmission. AIDS Research and Human Retroviruses, 2006, 22, 83-92.	0.5	34
104	Emergence of Antiretroviral Therapy Resistance-Associated Primary Mutations Among Drug-Naive HIV-1-Infected Individuals in Rural Western Cameroon. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 43, 15-22.	0.9	32
105	A new subtype (subgenotype) Ac (A3) of hepatitis B virus and recombination between genotypes A and E in Cameroon. Journal of General Virology, 2005, 86, 2047-2056.	1.3	159
106	Active Generation and Selection for HIV Intersubtype A/D Recombinant Forms in a Coinfected Patient in Kenya. AIDS Research and Human Retroviruses, 2004, 20, 255-258.	0.5	17
107	Genetic Diversity of HIV Type 1 in Likasi, Southeast of the Democratic Republic of Congo. AIDS Research and Human Retroviruses, 2004, 20, 1352-1357.	0.5	23
108	Genetic Diversity of HIV Type 1 in Rural Eastern Cameroon. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 37, 1641-1650.	0.9	38

7

#	Article	IF	CITATIONS
109	HIV Type 1 Infection in Pygmy Hunter Gatherers Is from Contact with Bantu Rather Than from NonHuman Primates. AIDS Research and Human Retroviruses, 2003, 19, 435-439.	0.5	16
110	Identification ofenvCRF-10 among HIV Variants Circulating in Rural Western Kenya. AIDS Research and Human Retroviruses, 2003, 19, 161-165.	0.5	19
111	Natural Infection of Wild-Born Mandrills (Mandrillus sphinx) with Two Different Types of Simian Immunodeficiency Virus. AIDS Research and Human Retroviruses, 2001, 17, 1143-1154.	0.5	38